Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy

Analysis of colorectal cancer‐related mutations by liquid biopsy: Utility of circulating cell‐free DNA and circulating tumor cells

(2019) Kohki Takeda et al.   CANCER SCIENCE

Circulating cell-free long DNA fragments predict post-hepatectomy recurrence of colorectal liver metastases

(2019) Takuma Iwai et al.   EJSO

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

(2018) Rona Yaeger et al.   CANCER CELL

Impact of Emergent Circulating Tumor DNARASMutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer

(2018) Tae Won Kim et al.   CLINICAL CANCER RESEARCH

Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer

(2018) Hiroyasu Furuki et al.   EJSO

Liquid Biopsy for the Management of Patients with Colorectal Cancer

(2018) Takeshi Yamada et al.   DIGESTION

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients

(2017) Masami Yamauchi et al.   INTERNATIONAL JOURNAL OF CANCER

Utility ofKRASmutation detection using circulating cell-free DNA from patients with colorectal cancer

(2016) Takeshi Yamada et al.   CANCER SCIENCE

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

(2016) Filippo Pietrantonio et al.   CLINICAL CANCER RESEARCH

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

(2016) Beth O. Van Emburgh et al.   Nature Communications

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

(2015) M. P. Morelli et al.   ANNALS OF ONCOLOGY

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

(2015) Takayuki Yoshino et al.   EBioMedicine

Concordant analysis of KRAS, BRAF, PIK3CA mutations and PTEN expression between primary colorectal cancer and matched metastases

(2015) Chen Mao et al.   Scientific Reports

Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA,KRASandBRAFin the plasma

(2014) Karen-Lise Garm Spindler et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

(2014) Alain R Thierry et al.   NATURE MEDICINE

Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

(2013) V. Taly et al.   CLINICAL CHEMISTRY

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

(2013) Hubert Piessevaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

(2008) D. Santini et al.   ONCOLOGIST